# New Psilocybin-Like Drugs for Brain Receptor Diseases > This patent describes new chemical compounds similar to psilocin, found in 'magic mushrooms,' designed to activate specific brain receptors for treating various diseases. - **Patent:** US 12735386 - **Original title:** Psilocybin analogs, salts, compositions, and methods of use - **Granted:** 2026 - **Status:** Active - **Times cited:** 0 - **Field:** biotech, pharmaceutical, neuroscience ## What it does This patent focuses on creating new chemical compounds, referred to as "psilocin compounds" or "analogs," that are chemically similar to psilocin. These compounds are designed to act as "serotonin 5-HT2 receptor agonists," meaning they activate specific serotonin receptors in the brain. The goal is to use these new compounds in "pharmaceutical compositions" to treat medical conditions associated with these 5-HT2 receptors. For example, a new psilocin analog could be formulated into a pill to treat a mental health condition like depression, aiming to provide therapeutic benefits by modulating brain activity through these specific receptors. Due to the lack of available claims text, specific claim elements cannot be referenced. ## What it does NOT cover - Does not cover natural psilocybin or psilocin compounds, only their specific synthetic 'analogs' or derivatives. - Does not cover compounds that do not primarily function as 'serotonin 5-HT2 receptor agonists'. - Does not cover non-chemical or non-pharmaceutical treatments for diseases associated with 5-HT2 receptors. - Does not cover methods of use that are not for the treatment of diseases. ## The clever bit The novelty lies in synthesizing new chemical structures, or 'analogs,' of psilocin. These analogs are engineered to interact with the brain's serotonin 5-HT2 receptors in specific ways, potentially offering advantages like improved stability, controlled duration of action, or reduced unwanted side effects compared to the natural compound. ## Real-world examples 1. Novel psychedelic-assisted therapies for major depressive disorder 2. Drug candidates for generalized anxiety disorder 3. Pharmaceutical formulations for post-traumatic stress disorder (PTSD) treatment 4. Compounds for cluster headache treatment ## Why it matters Psilocybin and related compounds are being extensively researched for their potential to treat serious mental health conditions like depression, anxiety, and PTSD. This patent contributes to the development of novel drug candidates that could offer improved therapeutic profiles, such as better safety, efficacy, or duration of action, compared to naturally occurring psychedelics. It aims to expand the toolkit for addressing significant unmet medical needs in psychiatry and neurology. ## Frequently asked questions ### What does New Psilocybin-Like Drugs for Brain Receptor Diseases cover? This patent describes new chemical compounds similar to psilocin, found in 'magic mushrooms,' designed to activate specific brain receptors for treating various diseases. ### When does this patent expire? This patent is expected to expire on September 15, 2046, when the invention enters the public domain. ### What problem does this patent solve? Psilocybin and related compounds are being extensively researched for their potential to treat serious mental health conditions like depression, anxiety, and PTSD. This patent contributes to the development of novel drug candidates that could offer improved therapeutic profiles, such as better safety, efficacy, or duration of action, compared to naturally occurring psychedelics. It aims to expand the toolkit for addressing significant unmet medical needs in psychiatry and neurology. ### What does this patent NOT cover? Does not cover natural psilocybin or psilocin compounds, only their specific synthetic 'analogs' or derivatives. **Full plain-English explainer:** https://patentbrief.org/patent/us/12735386/psilocybin-analogs-salts-compositions-and-methods-of-use **Original patent:** https://patents.google.com/patent/US12735386 --- _Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._ ## Related patents Semantically similar inventions in the PatentBrief corpus: - [Chemical Compounds to Block a Specific KRAS Cancer Gene](https://patentbrief.org/patent/us/12735425/67-dihydro-pyrano23-dpyrimidine-inhibitors-of-kras-g12c-mutant) — This patent describes new chemical compounds designed to stop a specific mutated protein called KRAS G12C, which is often found in various cancers, potentially offering new ways to treat the disease. - [Improving How Blood Platelets Are Stored](https://patentbrief.org/patent/us/12733635/platelet-storage-methods-and-compositions) — This patent describes new chemical compounds and methods to prevent damage to blood platelets when they are stored, like in blood banks, making them last longer and more effective for transfusions. - [Treating Lewy Body Dementia by Targeting Patients Without Tau Protein](https://patentbrief.org/patent/us/12734174/treatment-of-a-selective-population-of-patients-having-dementia-with-lewy-bodies) — This patent describes a method to treat a specific type of Dementia with Lewy Bodies in patients who don't have a lot of another brain protein called tau, using a special kind of drug. - [How Oligonucleotides Target C9orf72 for Brain Diseases](https://patentbrief.org/patent/us/12735703/oligonucleotide-compositions-and-methods-of-use-thereof) — This patent describes using special genetic molecules called oligonucleotides to treat brain diseases like ALS and FTD by targeting a specific gene called C9orf72. - [Treating Niemann-Pick Type C with a Special Sugar Mixture](https://patentbrief.org/patent/us/12734191/hydroxypropyl-beta-cyclodextrin-compositions-and-methods-12734191) — This patent describes specific mixtures of modified beta-cyclodextrin molecules designed for direct delivery to the brain to treat the rare genetic disorder Niemann-Pick disease Type C.